Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Novo Nordisk A/S

NVO ✗ NOT COMPLIANT ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Mega Cap Analyst: HOLD

Last Close

$45.89

▼ -1.78%

Market Cap $202.95B · Vol 1.65M

Key Metrics

P/E Ratio

11.36

FWD: 13.29

Market Cap

$202.95B

Mega Cap

Div Yield

3.97%

Semi-annual dividend

EPS Growth

-5.15%

YoY

RSI (14)

37.60

Momentum

Beta

0.75

vs Market

52W High

$64.16

28.48% below

52W Low

$35.13

30.63% above

Volume

1.65M

Avg 1.72M

P/B

7.41

Price-to-book

ROE

60.70%

Return on equity

Free Float

99.99%

Public shares

Shariah Compliance8 STANDARDS

✗ Novo Nordisk A/S (NVO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NVO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.90%

-6.48%

+0.20%

-7.42%

YTD

-9.81%

-9.93%

-50.42%

-10.69%

Financials & Valuation

TTM · Annual

Total Revenue	$48.60B
Net Income	$16.11B
Revenue Growth (YoY)	+4.55%
Gross Margin	82.51%
Operating Margin	46.26%
Net Profit Margin	33.14%
ROE	60.70%
ROA · ROIC	25.88% · 37.46%

P/E Ratio	11.36
Forward P/E (FY1)	13.29
PEG Ratio	2.42
P/S	4.85
P/B	7.41
P/FCF	51.66
EPS Growth	-5.15%
Outstanding Shares	3.39B

Technical Indicators

50-Day SMA	$47.23
200-Day SMA	$46.53
RSI (14)	37.60
Beta	0.75
52-Week High	$64.16
52-Week Low	$35.13

Volume Today	1.65M
Avg Daily Volume (30D)	1.72M
Relative Volume	0.96x
Volatility (10D)	40.05
Volatility (30D)	40.31
Free Float	99.99%

Analyst Consensus

HOLD

Current Price $45.89

Mean Target $49.85

52W Low$35.13 52W High$64.16

Current

Target

$35.13 $64.16

Current Analyst target

+8.62% upside potential · 22 analysts

Identifiers

ExchangeNYSE

FIGIBBG001S5TSK0

ISINUS6701002056

CountryDenmark

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.